Aplagon Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5.57M

  • Investors
  • 5

Aplagon General Information

Description

Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling medical professionals to provide patients with effective antithrombotic medicines with safety advantages.

Contact Information

Website
www.aplagon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biomedicum Helsinki 2A
  • Tukholmankatu 8 A
  • 00290 Helsinki
  • Finland
+358 040
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Biomedicum Helsinki 2A
  • Tukholmankatu 8 A
  • 00290 Helsinki
  • Finland
+358 040

Aplagon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aplagon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 16-Jun-2026 $5.57M Completed Clinical Trials - Phase 1
11. Secondary Transaction - Private 01-Mar-2026 Completed Clinical Trials - Phase 1
10. Later Stage VC 03-Feb-2025 Completed Clinical Trials - Phase 1
9. Grant 16-Nov-2022 Completed Clinical Trials - Phase 1
8. Equity Crowdfunding 28-Apr-2021 Completed Clinical Trials - Phase 1
7. Later Stage VC 24-Oct-2019 Completed Startup
6. Later Stage VC 02-Nov-2018 Completed Startup
5. Later Stage VC 12-May-2017 Completed Startup
4. Later Stage VC 26-Jul-2016 $757K Completed Startup
3. Later Stage VC 09-Jun-2015 $698K $757K Completed Startup
To view Aplagon’s complete valuation and funding history, request access »

Aplagon Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 35,715 $20.87 $20.87 1x $20.87 6.4%
Ordinary 75,000 $0.67 $0.67 1x $0.67 13.44%
To view Aplagon’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Aplagon Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Aplagon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4149488-A1 An antithrombic molecule having apac activity for the prevention and/or treaetment of thrombocytopenia Active 12-May-2020
WO-2021228866-A1 An antithrombic molecule having apac activity for the prevention and/or treaetment of thrombocytopenia Inactive 12-May-2020
AU-2021270349-A1 An antithrombic molecule having apac activity for the prevention and/or treatment of thrombocytopenia Active 12-May-2020
AU-2021270349-B2 An antithrombic molecule having apac activity for the prevention and/or treatment of thrombocytopenia Active 12-May-2020
CA-3173079-A1 An antithrombic molecule having apac activity for the prevention and/or treatment of thrombocytopenia Pending 12-May-2020 A61K31/727
To view Aplagon’s complete patent history, request access »

Aplagon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aplagon Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fåhraeus Startup and Growth Venture Capital Minority
European Innovation Council Accelerator/Incubator Minority
Gösta Serlachius Fine Arts Foundation Corporation Minority
Jenny and Antti Wihuri Foundation Limited Partner Minority
Innovestor Venture Capital Minority
To view Aplagon’s complete investors history, request access »

Ready to get started?

Request a free trial

Aplagon FAQs

  • When was Aplagon founded?

    Aplagon was founded in 2009.

  • Where is Aplagon headquartered?

    Aplagon is headquartered in Helsinki, Finland.

  • What is the size of Aplagon?

    Aplagon has 8 total employees.

  • What industry is Aplagon in?

    Aplagon’s primary industry is Drug Discovery.

  • Is Aplagon a private or public company?

    Aplagon is a Private company.

  • What is Aplagon’s current revenue?

    The current revenue for Aplagon is .

  • How much funding has Aplagon raised over time?

    Aplagon has raised $19.2M.

  • Who are Aplagon’s investors?

    Fåhraeus Startup and Growth, European Innovation Council, Gösta Serlachius Fine Arts Foundation, Jenny and Antti Wihuri Foundation, and Innovestor have invested in Aplagon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process